Agendia News and Press Releases


For all media and investor relations inquiries, please contact:

Hans Herklots

Head of Corporate Communications

Telephone: +31 20 462 1557

Email: hans.herklots@agendia.com

<<  <  1  2  3  >  >> View All

Sort by Date Sort by Article
12/17/09 FDA Broadens Clearance for Agendia's MammaPrint
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, December 17, 2009 –Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians. Over the past three years, the FDA has issued four clearances for MammaPrint, covering all aspects of this important service.
12/08/09 Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, December 8, 2009 -- Agendia, a world leader in molecular cancer diagnostics, announced today that it will be presenting six studies focusing on MammaPrint® at the 2009 San Antonio Breast Cancer Symposium (SABCS), one of the premiere conferences in breast cancer research worldwide. The SABCS will take place December 9-13, at the Henry B. Gonzalez Convention Center in San Antonio, Texas, USA.
12/01/09 Medicare Administrator Establishes Reimbursement Coding Policy for Agendia’s Breast Cancer Recurrence Test MammaPrint®
HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, December 1, 2009 –Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California’s Part B Medicare administrator, has established coding guidelines for the company’s MammaPrint test. MammaPrint is Agendia’s FDA-cleared breast cancer recurrence test, which has been reimbursed by payors since 2008.
09/23/09 Agendia raises US $23 million in series E financing
Company to present at UBS Global Life Sciences Conference on Sept. 23

HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, September 22, 2009 –Agendia, a world leader in molecular cancer diagnostics, today announced the successful closing of a US $23 million series E investment. The financing round was led by ...
06/23/09 Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility

HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, June 23, 2009 – Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast cancer recurrence test MammaPrint in St. Gallen’s ...